References

  1. Barnholtz-Sloan, J.S., et al., Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol, 2004. 22(14): p. 2865-72.

  2. Cagney, D.N., et al., Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol, 2017. 19(11): p. 1511-1521.

  3. Davis, F.G., et al., Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol, 2012. 14(9): p. 1171-7.

  4. Singh, R., et al., Epidemiology of synchronous brain metastases. Neurooncol Adv, 2020. 2(1): p.vdaa041.

  5. Schouten, L.J., et al., Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer, 2002. 94(10): p. 2698-705.

  6. Smedby, K.E., et al., Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer, 2009. 101(11): p. 1919-24.

  7. Nieder, C., et al., Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer, 2011. 117(11): p. 2505-12.

  8. Tabouret, E., et al., Recent trends in epidemiology of brain metastases: an overview. Anticancer Res, 2012. 32(11): p. 4655-62.

  9. Tsui, D.C.C., D.R. Camidge, and C.G. Rusthoven, Managing Central Nervous System Spread of Lung Cancer: The State of the Art. J Clin Oncol, 2022. 40(6): p. 642-660.

  10. Wu MY, Zhang EW, Strickland MR, Mendoza DP, Lipkin L, Lennerz JK, Gainor JF, Heist RS, Digumarthy SR. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. Cancers (Basel). 2021 Jul 16;13(14):3572. doi: 10.3390/cancers13143572. PMID: 34298783; PMCID: PMC8304953.

  11. Spira AI, Tu H, Aggarwal S, Hsu H, Carrigan G, Wang X, Ngarmchamnanrith G, Chia V, Gray JE. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Lung Cancer. 2021 Sep;159:1-9. doi: 10.1016/j.lungcan.2021.05.026. Epub 2021 May 25. PMID: 34293517.

  12. Chen S, Hua X, Jia J, Wu Y, Wei S, Xu L, Han S, Zhang H, Zhu X. Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies. Ann Palliat Med. 2021 Apr;10(4):3657-3672. doi: 10.21037/apm-20-1722. Epub 2021 Apr 1. PMID: 33832315.

  13. Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. Int J Mol Sci. 2016 Dec 18;17(12):2132. doi: 10.3390/ijms17122132. PMID: 27999344; PMCID: PMC5187932.

  14. Vassella E, Kashani E, Zens P, Kündig A, Fung C, Scherz A, Herrmann E, Ermis E, Schmid RA, Berezowska S. Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations. Eur J Cancer. 2021 Dec;159:227-236. doi: 10.1016/j.ejca.2021.10.006. Epub 2021 Nov 13. PMID: 34781171.

  15. Magnuson, A., Bruinooge, S. S., Singh, H., Wilner, K. D., Jalal, S., Lichtman, S. M., ... & Garrett-Mayer, E. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group Broadened Eligibility: Performance Status. Clinical Cancer Research, 27(9), 2424-2429.

  16. Mogenet, A., et al., Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. Lung Cancer, 2022. 169: p. 31-39.

  17. Huang, R.S.P., et al., Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022.

  18. Kemper, E.M., et al., Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer, 2004. 40(8): p. 1269-74.

  19. ten Tije, A.J., et al., Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs, 2004. 15(7): p. 715-8.

  20. Bernatz S, Ilina EI, Devraj K, Harter PN, Mueller K, Kleber S, Braun Y, Penski C, Renner C, Halder R, Jennewein L, Solbach C, Thorsen F, Pestalozzi BC, Mischo A, Mittelbronn M. Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases. J Exp Clin Cancer Res. 2019 Oct 29;38(1):434. doi: 10.1186/s13046-019-1427-1. PMID: 31665089; PMCID: PMC6819416.

  21. Matsumoto, K., et al., Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res, 2021. 10(4): p. 1642-1652.

  22. Furuya, N., et al., The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Oncology, 2020. 98(9): p. 661-668.

  23. Sabari, J.K., et al., Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models And Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res, 2022. 28(15): p. 3318-3328.

  24. Cui, W., et al., Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer, 2020. 146: p. 310-317.

  25. Ramalingam, S.S., et al., Efficacy of sotorasib in KRAS p.G12C-mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK100. . 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract P52.03.

  26. Jänne, P.A., et al., Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med, 2022. 387(2): p. 120-131.

  27. Sabari, J.K., et al., Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. Journal of Clinical Oncology, 2022. 40(17_suppl): p. LBA9009-LBA9009.

  28. Kim ES, et al., Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2. PMID: 28968170; PMCID: PMC5692724.

  29. Kim ES, et al., Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 May 1;27(9):2394-2399. doi: 10.1158/1078-0432.CCR-20-3852. Epub 2021 Feb 9. PMID: 33563632.